Next, we used lapatinib, a pharmacological inhibitor of ErbB2 phosphorylation to induce pathway inactivation and determine whether cardiac hypertrophy in ErbB2 transgenic mice is dependent on translation pathway activation. The gene discussed is ERBB2; the disease is cardiac hypertrophy.